1. Cell Cycle/DNA Damage
    Metabolic Enzyme/Protease
  2. HSP

Alvespimycin hydrochloride (Synonyms: 17-DMAG; KOS-1022; NSC 707545)

Cat. No.: HY-12024 Purity: 99.32%
Data Sheet SDS Handling Instructions

Alvespimycin hydrochloride is a potent inhibitor of Hsp90, binding to Hsp90 with EC50 of 62±29 nM.

For research use only. We do not sell to patients.
Alvespimycin hydrochloride Chemical Structure

Alvespimycin hydrochloride Chemical Structure

CAS No. : 467214-21-7

Size Price Stock Quantity
10 mM * 1 mL in DMSO $55 In-stock
10 mg $50 In-stock
25 mg $100 In-stock
100 mg $250 In-stock
200 mg $410 In-stock
500 mg $800 In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

Other Forms of Alvespimycin hydrochloride:

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Alvespimycin hydrochloride is a potent inhibitor of Hsp90, binding to Hsp90 with EC50 of 62±29 nM.

IC50 & Target

EC50: 62 nM±29 nM (Hsp90)[1]

In Vitro

Alvespimycin (17-DMAG) hydrochloride inhibits the growth of the human cancer cell lines SKBR3 and SKOV3, which overexpress Hsp90 client protein Her2, and causes down-regulation of Her2 as well as induction of Hsp70 consistent with Hsp90 inhibition, for Her2 degradation with EC50 of 8±4 nM and 46±24 nM in SKBR3 and SKOV3 cells, respectively; for Hsp70 induction with EC50 of 4±2 nM and 14±7 nM in SKBR3 and SKOV3 cells, respectively[1]. Compared with the vehicle control, 17-DMAG exerts dose-dependent apoptosis (P<0.001 averaged across 24- and 48-hour time points) at concentrations of 50nM to 500nM, which represent pharmacologically attainable doses. Similar to many other agents, 17-DMAG also demonstrates time-dependent apoptosis (P <0.001, averaged across all doses) in chronic lymphocytic leukemia (CLL) cells with extended exposure from 24 to 48 hours. In addition, 17-DMAG is much more potent after 24 and 48 hours of treatment than 17-AAG[2].

In Vivo

The tumors are grown for two months before the start of i.p. injections every four days over one month with 0, 50, 100 and 200 mg/kg dipalmitoyl-radicicol or 0, 5, 10 and 20 mg/kg 17-DMAG. Despite sample heterogeneity, the HSP90 inhibitor-treated animals have significantly lower tumour volumes than the vehicle control-treated animals. HSP90 inhibitors have been shown to cause liver toxicity in an animal model of gastrointestinal cancer. Nevertheless, the reduction in tumor size using dipalmitoyl-radicicol is statistically significant at 100 mg/kg, while 17-DMAG at either 10 or 20 mg/kg elicited a significant reduction in tumor size[3].

Clinical Trial
View MoreCollapse
References
Preparing Stock Solutions
Concentration Volume Mass 1 mg 5 mg 10 mg
1 mM 1.5309 mL 7.6545 mL 15.3090 mL
5 mM 0.3062 mL 1.5309 mL 3.0618 mL
10 mM 0.1531 mL 0.7655 mL 1.5309 mL
Please refer to the solubility information to select the appropriate solvent.
Cell Assay
[2]

Alvespimycin (17-DMAG) is dissolved in DMSO and stored, and then diluted with appropriate media before use[2].

MTT assays are performed to determine cytotoxicity. A total of 1×106 CD19-selected B cells from CLL patients are incubated for 24 or 48 hours in 17-DMAG, 17-AAG, or vehicle. MTT reagent is then added, and plates are incubated for an additional 24 hours before spectrophotometric measurement. Apoptosis is determined by staining with annexin V-fluorescein isothiocyanate and propidium iodide (PI). After exposure to drugs, cells are washed with phosphate-buffered saline and stained in 1 time binding buffer. Cell death is assessed by flow cytometry using a Beckman-Coulter model EPICS XL cytometer. Data are analyzed with the System II software package. A total of 10 000 cells are counted for each sample. Mitochondrial membrane potential changes are assessed by staining with the lipophilic cationic dye JC-1 and analysis by flow cytometry[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[3]

Alvespimycin (17-DMAG) is prepared in sesame oil (Mice)[3].

Mice[3]
Young male CB-17/IcrHsd-Prkdc-SCID mice, are used. Recombinant xenografts are made by mixing 1×105 BPH1 cells and 2.5×105 CAF per graft in collagen solution, allowed to gel, covered with medium and cultured overnight. Tumors are allowed to form over eight weeks, and then treated for four weeks with three different doses of dipalmitoyl-radicicol (50, 100 and 200 mg/kg) and 17-DMAG (5, 10 and 20 mg/kg) via intraperitoneal injections of compounds in sesame oil every four days. After 12 weeks in total, the mice are sacrificed, their kidneys resected, grafts cut in half and photographed before processing for histology. Graft dimensions are measured and the resultant tumour volume is calculated using the formula; volume=width×length×depth×π/6. This formula represents a conservative approach to evaluate tumour volumes, as it understates the volume of large, invasive tumours compared with smaller, non-invasive tumours. Resected grafts are fixed in 10% formalin, embedded in paraffin and processed for immunohistochemistry. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
Molecular Weight

653.21

Formula

C₃₂H₄₉ClN₄O₈

CAS No.

467214-21-7

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 50 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Purity: 99.32%

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Alvespimycin hydrochloride
Cat. No.:
HY-12024
Quantity: